Last reviewed · How we verify
Aplisol (TUBERCULIN)
At a glance
| Generic name | TUBERCULIN |
|---|---|
| Sponsor | ENDO USA, Inc. |
| Drug class | Skin Test Antigen [EPC] |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- infection with Mycobacterium tuberculosis
- TB disease
- M. tuberculosis infections
- TB infection
Common side effects
- Scarring
- Anaphylaxis/anaphylactoid reactions
- Rash
- Urticaria
- Edema/angioedema
- Pruritus
- Erythema
- Necrosis
- Ulceration
- Vesiculation
- Pain
- Discomfort
Drug interactions
- corticosteroids or immunosuppressive agents
- live virus vaccines (measles, mumps, rubella, oral polio, yellow fever, and varicella)
Key clinical trials
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2,PHASE3)
- Training Protocol on the Natural History of Tuberculosis
- The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis (NA)
- PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
- Online Transdiagnostic Group CBT for Postpartum Depression and Anxiety (NA)
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
- Intralipid® 20% for Reversal of Local Anesthetics (PHASE4)
- The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aplisol CI brief — competitive landscape report
- Aplisol updates RSS · CI watch RSS
- ENDO USA, Inc. portfolio CI